Trump announces trade deal with EU following months of negotiations
Max de Groen, a director at Nutanix, Inc. (NASDAQ:NTNX), recently sold a significant portion of his holdings in the company. According to a recent SEC filing, de Groen sold 5.5 million shares of Nutanix’s Class A common stock on March 4, 2025, at a price of $74.51 per share, totaling approximately $409.8 million. The sale comes as Nutanix trades near its 52-week high of $79.99, with the stock showing impressive momentum, up 28% over the past six months.
Following this transaction, de Groen’s indirect ownership through BCPE Nucleon (DE) SPV, LP now stands at 11,354,032 shares. Additionally, a separate transaction involved the distribution of 393,097 shares to members or partners of BCPE Nucleon for charitable purposes. This distribution did not involve any cash consideration. According to InvestingPro, Nutanix maintains impressive gross profit margins of 86% and operates with a moderate debt level, though the stock currently appears overvalued based on Fair Value analysis.
These transactions reflect de Groen’s ongoing management of his holdings in Nutanix, where he plays a key role as a partner at Bain Capital Investors, LLC, the ultimate general partner of BCPE Nucleon. With a market capitalization of $20.6 billion and analysts setting price targets up to $100, investors can access detailed insights and 13 additional ProTips through InvestingPro’s comprehensive research report.
In other recent news, Nutanix reported its financial results for the second quarter of fiscal year 2025, surpassing revenue expectations with a reported $655 million, compared to the forecasted $641.5 million. This strong performance was accompanied by an earnings per share of $0.46, slightly below the forecast of $0.47. Analyst firms have responded positively, with RBC Capital Markets raising Nutanix’s stock price target to $95 and Piper Sandler increasing it to $88, maintaining their Outperform and Overweight ratings, respectively. Needham also raised its price target to $92, noting Nutanix’s successful execution and strong demand, particularly in securing new deals within the Global 2000.
Raymond (NSE:RYMD) James increased its price target to $83, acknowledging Nutanix’s impressive billings recovery and third-quarter guidance that exceeded consensus. The company’s Annual Recurring Revenue (ARR) grew by 19% year-over-year, and free cash flow improvements were noted, suggesting potential for further upside. Nutanix has been gaining traction in the market, partly due to its strategic partnerships and a growing interest in replacing VMware (NYSE:VMW) solutions. The company’s focus on expanding its customer base and strengthening OEM partnerships has contributed to its robust financial health and optimistic outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.